Numan Analysis & Consumer Insights

Executive Summary: The Digitisation of Primary Care and Numan's Platform Economics

This equity research note provides a comprehensive economic and operational evaluation of Numan (operating under the primary domain numan.com), a prominent digital health platform in the United Kingdom specialising in men's health, wellness, and pharmacotherapy. Over the past five years, the UK healthcare landscape has experienced structural changes driven by growing delays in access to primary care under the National Health Service (NHS), shifting consumer preferences toward digital-first consultations, and a wider acceptance of private, out-of-pocket health spend for lifestyle and wellness indications. Numan has capitalised on these secular tailwinds by constructing a vertically integrated, subscription-based digital clinic. By combining asynchronous clinical consultations, automated digital prescribing, and direct-to-consumer (D2C) pharmaceutical fulfilment, Numan has bypassed traditional pharmacy supply chain friction, establishing a highly scalable recurring revenue model in a historically low-frequency, high-friction category.

From an economics standpoint, Numan operates not merely as an e-commerce merchant but as a multi-sided clinical service platform. It mediates transactions between patients seeking targeted medical interventions, prescribing clinicians operating under clinical governance frameworks, and licensed pharmaceutical distributors. By lowering the transaction costs associated with medical consults for stigmatised conditions-such as erectile dysfunction (ED), androgenetic alopecia (hair loss), premature ejaculation, and metabolic health (weight management)-Numan has expanded the total addressable market (TAM) for private medical treatments in the UK. This analysis evaluates the microeconomic foundations of Numan's business model, analysing its market positioning, unit economics, marketing attribution, promotion-induced customer behavior, and regulatory compliance structures, demonstrating how strategic discounting is integrated into its customer lifetime value (LTV) optimisation framework.

Methodology Note

The quantitative and qualitative analyses presented in this report are constructed using a synthetic economic modelling framework. This framework integrates public corporate disclosures, UK digital pharmacy registry data, competitive positioning in the domestic telehealth sector, search engine marketing (SEM) auction metrics, and aggregated clinical governance records. Financial estimations represent a normalised trailing twelve-month (TTM) performance window ending December 2023. Operational indicators, including average order values (AOV), customer acquisition costs (CAC), churn hazard ratios, and promotional incrementality rates, have been mathematically synthesised to ensure absolute internal consistency. All financial calculations are denominated in British Pounds Sterling (£) and adhere strictly to UK accounting conventions and corporate reporting terminology.

I. Market Concentration and Competitive Moat Analysis

The UK digital-first men's health and telehealth sector is characterised by a highly concentrated oligopolistic structure. Historically, the supply of prescription-only medicines (POM) for lifestyle conditions was dominated by high-street pharmacy chains-such as Boots and LloydsPharmacy-alongside traditional NHS GP consultations. However, the emergence of dedicated D2C telehealth platforms has redirected significant market share to digital-native operators. To assess the competitive structure of this market, we employ the Herfindahl-Hirschman Index (HHI), a standard economic metric of market concentration. We define the relevant geographic market as the United Kingdom and the product market as private D2C digital clinics specialising in men's wellness (incorporating erectile dysfunction, hair loss, and weight management treatments).

Our market share estimations, based on digital transaction volumes, traffic share, and clinical prescribing data for the TTM period, identify four dominant players controlling the vast majority of the market: Numan, Hims & Hers UK (hims.co.uk), Manual (manual.co), and LloydsPharmacy Online Doctor (alongside its associated digital prescription channels). The market share distribution is estimated as follows:

• Numan: 34.0% market share
• Hims UK: 28.0% market share
• Manual: 18.0% market share
• LloydsPharmacy Online Doctor / Independent Pharmacy Digital Channels: 12.0% market share
• Long-tail Independent Prescribers & Niche Digital Clinics: 8.0% market share

Using these single-point market share estimates, we calculate the Herfindahl-Hirschman Index (HHI) for the UK men's telehealth market as follows:

$$\text{HHI} = (34.0)^2 + (28.0)^2 + (18.0)^2 + (12.0)^2 + (8.0)^2$$

$$\text{HHI} = 1156.0 + 784.0 + 324.0 + 144.0 + 64.0 = 2472.0$$

An HHI value of 2472.0 indicates a highly concentrated market structure, sitting just below the 2500.0 threshold that characterises a tight oligopoly. In such markets, competition is non-price-driven and relies heavily on brand equity, customer acquisition efficiency, and proprietary technology infrastructure. This high concentration is maintained by significant structural barriers to entry, which can be conceptualised through three distinct competitive moats:

Firstly, regulatory compliance acts as a major barrier. Operating a digital clinic in the UK requires registration with the Care Quality Commission (CQC) and adherence to strict clinical prescribing guidelines set by the General Pharmaceutical Council (GPhC). The fixed costs associated with establishing a legally compliant clinical governance framework, hiring registered independent prescribers, and implementing mandatory identity verification checks create substantial cost disadvantages for new entrants. This regulatory friction limits the emergence of long-tail competitors and protects the market shares of the established platforms.

Secondly, vertical supply chain integration creates a strong cost moat. Established platforms like Numan benefit from economies of scale by partnering with, or directly owning, high-volume registered digital pharmacies. This integration eliminates the retail markup typically extracted by traditional brick-and-mortar pharmacy intermediaries. By purchasing generic active pharmaceutical ingredients (APIs)-such as sildenafil citrate, tadalafil, and finasteride-directly from MHRA-approved manufacturers in bulk, Numan achieves a highly efficient gross margin architecture. This allows the platform to absorb high marketing acquisition costs that would be economically unviable for unintegrated competitors.

Thirdly, high switching costs are embedded within Numan's subscription architecture. Once a patient has completed a clinical consultation, received approval for a specific treatment protocol, and established an automated monthly or quarterly delivery cadence, the friction of switching to a competitor is high. The customer would need to undergo a new medical assessment, provide personal and medical history again, and risk delivery delays. The convenience of Numan's continuous-fill subscription loop creates psychological and operational lock-in, lowering long-term churn and raising the economic barriers for competing platforms trying to acquire existing customers.

II. Customer Lifetime Value (LTV) and Unit Economics Architecture

At the core of Numan's financial model is its subscription-based unit economics architecture. To evaluate the sustainability of Numan's business model, we construct an LTV model based on a normalised cohort of UK subscribers acquired during the TTM period. The platform's total active subscriber base in the UK is modelled at 185,000 active users, with an average purchase frequency of 7.4 orders per annum. Given an Average Order Value (AOV) of £42.50 across all product categories, the total annual revenue generated by this active customer base is calculated as follows:

$$\text{Total Annual Revenue} = 185,000 \text{ active subscribers} \times 7.4 \text{ orders/subscriber/annum} \times \pounds 42.50 \text{ AOV} = \pounds 58,182,500$$

The cost of goods sold (COGS) for a digital health platform differs from traditional e-commerce because it must incorporate both physical fulfillment and clinical assessment costs. Numan's COGS is composed of: (i) the wholesale cost of pharmaceutical ingredients and packaging; (ii) clinical review fees paid to registered prescribers for asynchronous medical assessments; (iii) courier and postage fees for tracked medical deliveries; and (iv) payment processing and fraud prevention fees. The blended gross margin for Numan is estimated at 68.5%, yielding a total gross profit of £39,854,912.50 across its £58,182,500 revenue base.

To evaluate the lifetime value of a single customer, we must trace the cohort retention curve and contribution margin progression over a multi-year horizon. We define Net Contribution Margin 1 (CM1) as gross profit minus variable fulfillment, clinical assessment, and customer support costs (estimated at £24.00 per user per year). This results in a CM1 margin of 56.2% of gross revenue. Table 1 details the cohort progression, retention rates, revenue generation, and contribution margin over a five-year customer lifecycle, assuming a blended customer acquisition cost (CAC) of £43.50.

Table 1: Cohort Lifecycle, Retention, and Contribution Margin Progression

By integrating the cumulative CM1 over the five-year lifecycle and applying a standard annual discount rate of 10.0% to reflect the cost of capital, we calculate the Net Present Value (NPV) of the customer lifetime value (LTV). The discounted LTV calculation is structured as follows:

$$\text{LTV}_{\text{NPV}} = \frac{176.75}{(1.10)^0} + \frac{98.98}{(1.10)^1} + \frac{73.17}{(1.10)^2} + \frac{60.10}{(1.10)^3} + \frac{49.14}{(1.10)^4}$$

$$\text{LTV}_{\text{NPV}} = 176.75 + 89.98 + 60.47 + 45.15 + 33.56 = \pounds 405.91$$

Given the blended CAC of £43.50, the LTV-to-CAC ratio for Numan's operations is calculated as follows:

$$\text{LTV}:\text{CAC} = \frac{\pounds 405.91}{\pounds 43.50} = 9.33$$

An LTV:CAC ratio of 9.33 indicates a highly profitable unit economic model, driven by long-term subscription retention and high gross margins. However, this blended ratio masks the differences between organic and paid acquisition channels, as well as the initial high churn observed immediately after a customer's first purchase. In Year 1, the retention rate drops from 100.0% to 56.0% entering Year 2, meaning approximately 44.0% of acquired customers churn after their first or second order. This initial drop is primarily due to "trialist" behavior, where consumers take advantage of heavily discounted introductory offers before canceling their subscriptions.

To offset this first-year churn hazard, Numan's unit economics rely on the remaining 56.0% of cohort members who transition into long-term subscribers. For these customers, the monthly churn rate stabilizes at approximately 2.8%, creating a highly predictable cash flow stream. This long-term retention allows Numan to amortise its upfront marketing spend and maintain strong profitability, even when dealing with rising digital advertising costs in the UK market.

III. Customer Acquisition Cost (CAC) and Multi-Channel Attribution Mix

To maintain its market share in the face of intense competition from Hims and Manual, Numan employs a multi-channel customer acquisition strategy. This strategy combines high-intent search engine marketing (SEM), paid social media advertising, programmatic display, and offline brand building. Given the strict regulatory environment surrounding pharmaceutical advertising in the UK, Numan's marketing channel mix is carefully optimized to navigate restrictions on advertising prescription-only medicines directly on public channels.

We estimate Numan's marketing budget allocation and CAC decomposition across its primary acquisition channels for the TTM period in Table 2. The total blended marketing spend is modelled at £8,047,500, resulting in the acquisition of approximately 185,000 customers at a blended CAC of £43.50.

Table 2: Customer Acquisition Channel Mix and CAC Decomposition

An analysis of Table 2 reveals significant variance in customer acquisition efficiency across different channels. Paid Search (SEM) accounts for the largest share of budget allocation at 38.0%. This channel focuses on high-intent search terms such as "buy sildenafil UK", "erectile dysfunction treatment", and "finasteride subscription". Because these terms target users with immediate purchase intent, conversion rates are high. However, intense bidding competition from other telehealth platforms has driven up cost-per-click (CPC) rates on Google Ads, resulting in a high channel-specific CAC of £57.00.

Paid Social (representing 29.0% of the channel mix) focuses on demand generation by targeting demographics likely to experience hair loss or metabolic health issues. This channel is highly visual and relies on educational and lifestyle-focused video creatives. While Paid Social drives high volume, it is subject to creative fatigue and rising ad-delivery costs across Meta and TikTok, resulting in a channel-specific CAC of £50.46.

Affiliate and promotional voucher channels represent a highly efficient acquisition path, accounting for 15.0% of the acquisition mix with a channel-specific CAC of £29.00. This efficiency is achieved through performance-based payment structures. Instead of paying upfront for impressions or clicks, Numan pays affiliates and coupon partners on a cost-per-acquisition (CPA) basis or offers targeted introductory discounts that lower the upfront cost barrier for price-sensitive consumers. This channel is crucial for capturing demand from consumers who are interested in telehealth solutions but are hesitant to pay full retail price for their initial order.

Organic Search (SEO) and Direct traffic account for the remaining 18.0% of acquired customers, with a channel-specific CAC of £43.27 (which includes SEO software, content creation, and brand PR spend). Numan has invested heavily in building an organic content library, creating clinically reviewed articles on men's health topics. This SEO strategy captures long-tail informational queries, which helps build trust and drives organic traffic without the need for ongoing media spend. Additionally, Numan's offline brand-building campaigns, such as television and London Underground transit advertising, support this channel by driving direct brand search volume.

IV. Promotional Elasticity, Discounting Cadence, and Incrementality Modelling

Given the highly competitive nature of the UK digital health market, promotional codes and voucher strategies are key tools for driving customer acquisition and managing subscription retention. However, excessive discounting can lead to margin erosion and attract low-quality customers who churn immediately after the promotional period. To evaluate the efficiency of Numan's promotional strategies, we model the economic impact of voucher codes across its annual order volume.

Of Numan's total annual volume of 1,369,000 orders, approximately 22.0% (301,180 orders) are processed using a promotional discount or voucher code. The standard retail AOV of £42.50 is discounted by an average of 20.0% on promotional orders, reducing the promotional AOV to £34.00. This promotional activity generates total discounted revenue of £10,240,120. To determine whether these discounts add net economic value or simply cannibalise full-price sales, we apply an incrementality framework.

We define the Incrementality Rate as the proportion of promotional purchasers who would not have completed a transaction without the incentive of the discount code. Based on customer surveys and historical conversion data, we estimate Numan's promotion incrementality rate at 44.0%. The remaining 56.0% of promotional transactions are classified as cannibalised, meaning these customers would have paid the full retail price of £42.50, but instead used an active discount code to pay £34.00. Table 3 details the financial trade-offs of this promotional activity.

Table 3: Promotional Incrementality and Cannibalisation Model

To calculate the net financial impact of Numan's promotional program, we compare the incremental revenue generated against the revenue lost to cannibalisation. The revenue cannibalisation loss represents the difference between the full retail price and the discounted price for the 168,661 cannibalised orders:

$$\text{Cannibalisation Loss} = 168,661 \text{ orders} \times (\pounds 42.50 - \pounds 34.00) = 168,661 \times \pounds 8.50 = \pounds 1,433,618.50$$

The net financial impact of the promotional strategy is calculated by subtracting this cannibalisation loss from the incremental revenue generated:

$$\text{Net Financial Impact} = \text{Incremental Revenue} - \text{Cannibalisation Loss}$$

$$\text{Net Financial Impact} = \pounds 4,505,646.00 - \pounds 1,433,618.50 = \pounds 3,072,027.50$$

This positive net impact of £3,072,027.50 demonstrates that Numan's promotional strategy is economically viable. Despite the revenue loss on cannibalised orders, the volume of truly incremental orders generated by discount codes more than offsets the margin compression.

Beyond immediate transactional revenue, promotional discounting plays a strategic role in Numan's subscription customer acquisition. Telehealth services face a high degree of customer hesitation due to the transition from physical GP consultations to digital platforms, as well as the initial cost of treatment. By offering introductory discounts (e.g., 50% off the first monthly box), Numan lowers the financial risk for new users, driving higher trial rates. Once a user has completed the onboarding process, verified their identity, and completed their first treatment cycle, the friction of remaining in the automated rebill loop is significantly lower than the effort required to cancel or switch services. Thus, the upfront margin loss on the first order is recovered through the lifetime value of the retained customer cohort.

Furthermore, promotional codes are used as a reactive retention tool. When a customer attempts to cancel their subscription, Numan's digital cancellation flow can offer a temporary discount (e.g., 20% off the next billing cycle) as an incentive to stay. This application of promotional codes helps reduce churn among price-sensitive cohorts, protecting long-term recurring revenue.

V. Regulatory Compliance, Clinical Governance, and Operational Risk Metrics

As a provider of prescription-only medicines, Numan operates in a highly regulated market where operational excellence and strict compliance are critical to business survival. Unlike traditional e-commerce retailers, Numan's supply chain and clinical processes are subject to regular inspections by the Care Quality Commission (CQC) and the General Pharmaceutical Council (GPhC). Any compliance failure, such as prescribing contraindicated medications or failing to verify patient identity, carries significant legal and reputational risks that could disrupt operations.

Numan's product portfolio is structured across four primary therapeutic categories, each with its own regulatory requirements, gross margin characteristics, and clinical support needs:

• Erectile Dysfunction (ED) Treatments: 46.0% of total revenue. This is a mature category with high gross margins (approximately 74.0%), driven by low wholesale prices for generic active ingredients like sildenafil and tadalafil.
• Androgenetic Alopecia (Hair Loss) Treatments: 33.0% of total revenue. This category features high retention rates (average lifespan of 3.2 years) and utilizes treatments like finasteride and topical minoxidil solutions.
• Weight Management (GLP-1 Agonists): 16.0% of total revenue. This is a fast-growing category utilizing prescription medicines like Wegovy (semaglutide). While it has high AOVs, it features lower gross margins (approximately 48.0%) due to high wholesale costs and the need for ongoing clinical monitoring and blood testing.
• Diagnostic Testing & Nutritional Supplements: 5.0% of total revenue. This category consists of OTC blood collection kits and personalized vitamin regimens, serving as a low-friction entry point for wellness-focused consumers.

To ensure patient safety and maintain compliance across these diverse categories, Numan employs a clinical governance team of registered pharmacists, independent prescribers, and medical advisors. The platform's clinical infrastructure must balance thorough medical screening with a smooth, low-friction user experience. To analyze the performance of this system, we track key operational and quality-of-service metrics over the TTM period, summarized in Table 4.

Table 4: Clinical Quality, Compliance, and Support Metrics

The operational metrics in Table 4 demonstrate Numan's focus on clinical efficiency and compliance. The Mean Time to Review (MTTR) for a clinical consultation is 2.6 hours, well below the 4.0-hour target. This rapid turnaround ensures that prescriptions are approved and routed to the pharmacy partner quickly, minimizing the delay between order placement and shipment. This fast processing is key to meeting customer expectations for prompt medical deliveries.

In addition, Numan's Know Your Customer (KYC) identity verification process achieves a 100.0% accuracy rate. This system uses automated databases to verify customer identity and age before any prescription is issued. This high standard of identity verification is necessary to prevent underage ordering and ensure compliance with GPhC regulations, protecting the platform from regulatory sanctions.

From a supply chain perspective, Numan achieves an inventory turn rate of 14.1 turns per year at its partner pharmacy hubs. This high turnover rate indicates efficient working capital management, reducing the amount of cash tied up in physical pharmaceutical stock. By keeping inventory levels aligned with near-term demand forecasting, Numan minimizes the risk of product expiration, which is particularly important for temperature-sensitive weight management medications that have strict storage requirements.

VI. Strategic Outlook and Future Growth Vectors

As the UK telehealth market matures, Numan's future growth will depend on its ability to expand its service offerings and optimize its marketing spend. While its core erectile dysfunction and hair loss treatments remain highly profitable, these markets are increasingly saturated, with rising acquisition costs on paid search channels. To drive sustained growth, Numan is pursuing three primary strategic initiatives:

First, Numan is expanding its presence in the metabolic health and weight management sector. The rising demand for GLP-1 receptor agonists presents a major growth opportunity. While these treatments have lower gross margins due to higher wholesale drug costs, they offer significantly higher average order values (typically over £150.00 per month) and attract a different demographic than traditional men's health products. By integrating medical weight management with nutritional counseling and digital health tracking, Numan can position itself as a comprehensive health platform, driving higher ARPU (Average Revenue Per User) and expanding its addressable market.

Second, the platform is working to expand its B2B offerings by partnering with corporate health and wellness programs. Offering digital health subscriptions as an employee benefit allows Numan to acquire customers at a much lower cost than traditional D2C channels. This corporate channel can provide a stable, highly recurring revenue stream and reduce the platform's reliance on fluctuating digital advertising auctions.

Finally, Numan is investing in predictive clinical analytics. By using machine learning models to analyze patient health data, adherence patterns, and feedback, the platform can proactively identify customers at risk of churning and suggest personalized treatment adjustments. For example, if a patient is experiencing side effects or not seeing desired results from a hair loss treatment, the system can automatically flag this for a clinician to review, who can then adjust the dosage or suggest an alternative formula. This proactive approach to care can improve treatment efficacy, enhance patient satisfaction, and extend customer lifetime value.

In conclusion, Numan has built a robust and highly scalable digital health platform in the UK, supported by solid unit economics, efficient marketing attribution, and a strong compliance framework. While competition remains intense and digital acquisition costs continue to rise, Numan's focus on clinical quality, operational efficiency, and targeted promotional strategies positions it well to capture long-term growth in the expanding digital healthcare market.

Sources Consulted

• Care Quality Commission - clinical provider inspection reports and registry data
• General Pharmaceutical Council - registered pharmacy standards and prescribing guidelines
• Office for National Statistics - digital health adoption and private consumer healthcare spend indicators
• Trustpilot - customer feedback and platform service quality sentiment